보메뎀스타트(MK-3543-017)의 안전성 및 유효성 평가에 관한 연구
이전 Bomedemstat 임상 연구에 등록한 참가자의 치료에 대한 Bomedemstat의 안전성과 유효성을 평가하는 다기관, 공개 라벨, 확장 연구
The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator, and have shown the following criteria:
- Participants from the IMG-7289-202/MK-3543-005 (NCT05223920) study must have received at least 6 months of treatment with bomedemstat;
- Essential thrombocythemia (ET) and polycythemia vera (PV) participants from studies other than IMG-7289-202/MK-3543-005 must have achieved confirmed hematologic response.
No hypothesis testing will be conducted in this study.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Toll Free Number
- 전화번호: 1-888-577-8839
- 이메일: Trialsites@msd.com
연구 장소
-
-
-
Auckland, 뉴질랜드, 0622
- 모집하지 않고 적극적으로
- North Shore Hospital-Department of Haematology ( Site 1401)
-
Auckland, 뉴질랜드, 2025
- 모집하지 않고 적극적으로
- Aotearoa Clinical Trials ( Site 1400)
-
-
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- 모병
- University of Michigan ( Site 6000)
-
연락하다:
- Study Coordinator
- 전화번호: 734-763-4695
-
-
North Carolina
-
Durham, North Carolina, 미국, 27705
- 모병
- DUHS Duke Blood Cancer Center ( Site 6005)
-
연락하다:
- Study Coordinator
- 전화번호: 919-668-1608
-
-
Ohio
-
Columbus, Ohio, 미국, 43210
- 모병
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007)
-
연락하다:
- Study Coordinator
- 전화번호: 888-577-8839
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15232
- 모병
- UPMC Hillman Cancer Center ( Site 6004)
-
연락하다:
- Study Coordinator
- 전화번호: 412-864-6627
-
-
-
-
Hammersmith and Fulham
-
London, Hammersmith and Fulham, 영국, W12 0HS
- 모병
- Imperial College Healthcare NHS Trust - Hammersmith Hospital ( Site 3402)
-
연락하다:
- Study Coordinator
- 전화번호: +442083834340
-
-
Lincolnshire
-
Boston, Lincolnshire, 영국, PE21 9QS
- 모병
- Boston Pilgrim Hospital ( Site 3403)
-
연락하다:
- Study Coordinator
- 전화번호: 01205 446311
-
-
London, City of
-
London, London, City of, 영국, NW1 2PG
- 모병
- University College London Hospital ( Site 3400)
-
연락하다:
- Study Coordinator
- 전화번호: +442034472528
-
London, London, City of, 영국, SE1 9RT
- 모병
- Guy's & St Thomas' NHS Foundation Trust ( Site 3401)
-
연락하다:
- Study Coordinator
- 전화번호: +442071884259
-
-
-
-
-
Alessandria, 이탈리아, 15121
- 모병
- Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 2703)
-
연락하다:
- Study Coordinator
- 전화번호: +39 0131 206440
-
Bologna, 이탈리아, 40138
- 모병
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 2702)
-
연락하다:
- Study Coordinator
- 전화번호: +390512143044
-
Varese, 이탈리아, 21100
- 모병
- Ospedale di Circolo e Fondazione Macchi Varese ( Site 2701)
-
연락하다:
- Study Coordinator
- 전화번호: +390332393906
-
-
Tuscany
-
Florence, Tuscany, 이탈리아, 50134
- 모병
- Azienda Ospedaliera Universitaria Careggi ( Site 2700)
-
연락하다:
- Study Coordinator
- 전화번호: +39 0131 206440
-
-
-
-
New South Wales
-
Camperdown, New South Wales, 호주, 2050
- 모병
- Royal Prince Alfred Hospital ( Site 1003)
-
연락하다:
- Study Coordinator
- 전화번호: +61295155720
-
St Leonards, New South Wales, 호주, 2065
- 모병
- Royal North Shore Hospital ( Site 1001)
-
연락하다:
- Study Coordinator
- 전화번호: +61299264383
-
-
Queensland
-
Buderim, Queensland, 호주, 4556
- 모병
- Sunshine Coast Hematology and Oncology Clinic ( Site 1006)
-
연락하다:
- Study Coordinator
- 전화번호: +61754790000
-
Southport, Queensland, 호주, 4215
- 모병
- Gold Coast University Hospital-Cancer and Blood Disorders Clinical Trial Team ( Site 1002)
-
연락하다:
- Study Coordinator
- 전화번호: +61756872712
-
-
South Australia
-
Adelaide, South Australia, 호주, 5000
- 모병
- Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 1000)
-
연락하다:
- Study Coordinator
- 전화번호: +61870740000
-
-
Victoria
-
Clayton, Victoria, 호주, 3168
- 모병
- Monash Health ( Site 1004)
-
연락하다:
- Study Coordinator
- 전화번호: +61395956111
-
-
-
-
-
Hksar, 홍콩
- 모집하지 않고 적극적으로
- Queen Mary Hospital ( Site 1601)
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Is from a bomedemstat study sponsored by Imago BioSciences, Inc. (a subsidiary of Merck & Co., Inc.) or MSD, and established by the Sponsor as MK-3543-017 ready
- Has received at least 6 months of treatment with bomedemstat in the IMG-7289-202/MK-3543-005 study, while safely tolerating bomedemstat, and receiving clinical benefit from its use in the estimation of the investigator
- ET and PV participants from established feeder studies other than IMG-7289- 202/MK-3543-005 must have achieved confirmed hematologic response, must be safely tolerating bomedemstat, and must be receiving clinical benefit from its use in the estimation of the investigator
- Is not currently on a dose hold
- Participant must be able to swallow oral medication and follow instructions for at-home dosing of bomedemstat
Exclusion Criteria:
- Has received prohibited concomitant medications
- Ongoing or planned participation in another investigational study
- Has noncompliance in prior bomedemstat study receiving <90% of assigned doses excluding suspensions or holds as assigned by the investigator
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Bomedemstat
Participants will receive oral capsules of bomedemstat once daily for up to 10 years, with the starting dose as the same dose that the participant was on at the time of transition from the feeder study. |
10, 15, 20, and 50 mg oral capsules
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of participants with one or more adverse events (AEs)
기간: Up to ~10 years
|
An AE is any undesirable physical, psychological or behavioral effect experienced by a patient during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any untoward signs or symptoms experienced by the patient from the time of first dose with bomedemstat under this protocol until completion of the study. The percentage of participants with AEs will be presented. |
Up to ~10 years
|
|
Percentage of participants who discontinued study treatment due to an AE
기간: Up to ~10 years
|
An AE is any undesirable physical, psychological or behavioral effect experienced by a patient during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any untoward signs or symptoms experienced by the patient from the time of first dose with bomedemstat under this protocol until completion of the study. The percentage of participants who discontinued study treatment due to an AE will be presented. |
Up to ~10 years
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
For participants with ET: Duration of durable clinicohematologic response
기간: Up to ~10 years
|
For participants who demonstrate durable clinicohematologic response (DCHR) in their feeder study, duration of durable clinicohematologic response (DODCHR) is defined as the time from the first documented evidence of confirmed reduction of platelet and white blood cell (WBC) counts until confirmed increase of platelet and WBC counts to above acceptable threshold, thrombotic or major hemorrhagic events, or disease progression to myelofibrosis (MF), myelodysplastic syndrome (MDS), or acute myeloid leukemia (AML). DODCHR will be reported. |
Up to ~10 years
|
|
For participants with ET or PV: Duration of clinicohematologic response
기간: Up to ~10 years
|
For participants who showed clinicohematologic response in their feeder study, duration of clinicohematologic response is defined as the time from the first documented evidence of confirmed reduction of platelet and WBC count until confirmed increase of platelet and WBC counts to above acceptable threshold, thrombotic or major hemorrhagic events or disease progression to MF, MDS, or AML, or phlebotomy (PV participants only). The duration of clinicohematologic response will be reported. |
Up to ~10 years
|
|
For participants with ET or PV: Duration of hematologic response
기간: Up to ~10 years
|
For participants who showed confirmed hematologic response in their feeder study, duration of hematologic response is defined as the time from the first documented evidence of confirmed reduction of platelet and WBC count until confirmed increase of platelet and WBC counts to above acceptable threshold, or phlebotomy (PV participants only). The duration of hematologic response will be reported. |
Up to ~10 years
|
|
For participants with ET or PV: Percentage of participants with transformation to MF or MDS/AML
기간: Up to ~10 years
|
Disease Progression is defined as the transformation to post-ET myelofibrosis (ET participants only), post-PV myelofibrosis (PV participants only), spleen volume increase ≥25% (MF participants only), myelodysplastic syndrome, or acute myeloid leukemia as assessed by the investigator. The percentage of participants with transformation to MF or MDS/AML will be reported. |
Up to ~10 years
|
|
For participants with MF: Percentage of participants with worsening of splenomegaly or transformation to MDS/AML
기간: Up to ~10 years
|
Spleen volume will be assessed by magnetic resonance imaging (MRI) (or computed tomography [CT] where applicable) at pre-specified timepoints. The percentage of participants with worsening of splenomegaly or transformation to MDS/AML will be reported. |
Up to ~10 years
|
|
For participants with MF, ET, or PV: Percentage of participants with thrombotic events
기간: Up to ~10 years
|
Thrombotic events are defined as: new or recurrent acute myocardial infarction; unstable angina; stroke; transient ischemic attack (TIA); deep venous thrombosis (DVT); pulmonary embolism (PE); thrombotic digital ischemia; other thrombotic events such as peripheral limb ischemia or Budd-Chiari syndrome that are assessed to be due to underlying PV; other vascular occlusive events such as symptoms of cardiac, abdominal or peripheral limb ischemia supported by objective evidence of vessel disease and/or ischemia. The percentage of participants with thrombotic events will be presented. |
Up to ~10 years
|
|
For participants with MF, ET, or PV: Percentage of participants with major hemorrhagic events
기간: Up to ~10 years
|
Hemorrhagic events are defined as: Major Bleeding (MB) Events such as fatal bleeding, and/or symptomatic bleeding in a critical area or organ such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a fall in hemoglobin level of 2 g/dL or more, or leading to transfusion of 2 or more units of whole blood or red cells; Clinically Relevant Non-Major Bleeding (CRNMB) Events Leading to hospitalization or increased level of care or clinically important, prompting a face-to-face medical evaluation. The percentage of participants with major hemorrhagic events will be presented. |
Up to ~10 years
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Medical Director, Merck Sharp and Dohme LLC
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 3543-017
- U1111-1294-8621 (레지스트리 식별자: UTN)
- MK-3543-017 (기타 식별자: MSD)
- 2023-506996-89-00 (레지스트리 식별자: EU CT)
- 2023 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .